Beyond Air’s NeuroNOS Subsidiary Sale Sparks 150% Stock Surge

Beyond Air's stock (XAIR) skyrocketed 150% following the announcement of XTL Biopharmaceuticals' acquisition of an 85% stake in its NeuroNOS subsidiary. The deal, valued at up to $32.5 million, includes 19.9% of XTL's share capital, $1 million upfront cash, and milestone payments tied to clinical and commercial achievements.

NeuroNOS focuses on groundbreaking treatments for Autism Spectrum Disorder and brain cancer, leveraging small molecule drugs that penetrate the blood-brain barrier. The subsidiary's FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma underscore its potential, offering seven years of market exclusivity upon approval.

XTL Biopharmaceuticals shares ROSE 15.87% on the news, reflecting investor confidence in the strategic acquisition. The transaction's milestone structure—$5.5 million for clinical development and $26 million for commercial targets—aligns incentives with long-term success.